HIF/HIF Prolyl-Hydroxylase

Hypoxia-inducible factors; HIFs; HIF-PH

HIFs (Hypoxia-inducible factors) are transcription factors that respond to changes in available oxygen in the cellular environment, to be specific, to decreases in oxygen, or hypoxia. The HIF signaling cascade mediates the effects of hypoxia, the state of low oxygen concentration, on the cell. Hypoxia often keeps cells from differentiating. However, hypoxia promotes the formation of blood vessels, and is important for the formation of a vascular system in embryos, and cancer tumors. The hypoxia in wounds also promotes the migration of keratinocytes and the restoration of the epithelium. In general, HIFs are vital to development. In mammals, deletion of the HIF-1 genes results in perinatal death. HIF-1 has been shown to be vital to chondrocyte survival, allowing the cells to adapt to low-oxygen conditions within the growth plates of bones. HIF plays a central role in the regulation of human metabolism. Recently, several drugs that act as selective HIF prolyl-hydroxylase inhibitors have been developed.
HIF/HIF Prolyl-Hydroxylase Inhibitors, Agonists, Antagonists, Activators & Modulators

(Rac)-PT2399  
Cat. No.: HY-108697A  
(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC₅₀ of 0.01 μM.  
Purity: 99.42%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Acetylarenobufagin  
Cat. No.: HY-N6905  
Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-1) modulator.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg

Acriflavine  
Cat. No.: HY-100575  
Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic.  
Purity: 98.62%  
Clinical Data: Launched  
Size: 100 mg

AFP464  
Cat. No.: HY-16031  
AFP464 is an active inhibitor with an IC₅₀ of 0.25 μM, also is a potent aryl hydrocarbon receptor (AhR) activator.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg

Acriflavine  
Cat. No.: HY-100575  
Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic.  
Purity: 98.62%  
Clinical Data: Launched  
Size: 100 mg

AFPB464  
Cat. No.: HY-16031  
AFPB464 is an active HIF-1α inhibitor with an IC₅₀ of 0.25 μM, also is a potent aryl hydrocarbon receptor (AhR) activator.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg

AKBA (Acetyl-11-keto-β-boswellic acid)  
Cat. No.: HY-N0892  
AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.  
Purity: 99.71%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg

BAY 87-2243  
Cat. No.: HY-15836  
BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.  
Purity: 99.41%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chlorogenic acid  
Cat. No.: HY-N0055  
Chlorogenic acid is a major phenolic compound in coffee and tea.  
Purity: 99.29%  
Clinical Data: Phase 3  
Size: 10 mM × 1 mL, 500 mg

Daprodustat (GSK1278863)  
Cat. No.: HY-17608  
Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia associated with chronic kidney disease.  
Purity: 99.39%  
Clinical Data: Phase 3  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dencichine  
Cat. No.: HY-N1477  
Dencichine is a non-protein amino acid originally extracted from Panax notoginseng, and can inhibit HIF-prolyl hydroxylase-2 (PHD-2) activity.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 5 mg, 10 mg, 25 mg

Deoxyshikonin  
Cat. No.: HY-N2187  
Deoxyshikonin is isolated from Lithospermum erythrorhizon Sieb with antitumor activity.  
Purity: 99.75%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg
Desidustat
Cat. No.: HY-103227
Desidustat is an inhibitor of HIF hydroxylase extracted from patent WO 2014102818 A1, compound example 2.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

DMOG
(Dimethyloxallyl Glycine)
Cat. No.: HY-15893
DMOG (Dimethyloxallyl Glycine) is a cell-permeable and competitive inhibitor of HIF-1α prolyl hydroxylase (HIF-PH).

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Echinomycin
(Quinomycin A; NSC-13502)
Cat. No.: HY-106101
Echinomycin (Quinomycin A) is a potent small-molecule and cell-permeable inhibitor of hypoxia-inducible factor-1 (HIF-1) DNA-binding activity. Echinomycin selectively inhibits the cancer stem cells (CSCs) with an IC50 of 29.4 pM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enarodustat
(JTZ-951)
Cat. No.: HY-109057
Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM; Enarodustat has entered clinical trial for renal anemia.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

FG-2216
(IOX3; YM311)
Cat. No.: HY-15641
FG-2216 (IOX3; YM311) is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 μM for PDH2 enzyme; orally bioavailable and induced significant and reversible Epo induction in vivo.

Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fraxinellone
Cat. No.: HY-N0242
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamus dascyapus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Glucosamine
(D-Glucosamine, Chitosamine)
Cat. No.: HY-81125
Glucosamine (D-Glucosamine) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement.

Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Glucosamine hydrochloride
(D- (+)-Glucosamine hydrochloride; Chitosamine hydrochloride)
Cat. No.: HY-N0733
Glucosamine hydrochloride (D-Glucosamine hydrochloride) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement.

Purity: >98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg
Glucosamine sulfate (D-Glucosamine sulfate) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, and is used as a dietary supplement.

**Cat. No.: HY-N0487**

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

**GN44028**

**Cat. No.: HY-110266**

GN44028 is a hypoxia inducible factor (HIF)-1 inhibitor, with an IC$_{50}$ of 14 nM. GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity without suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization.

**Purity:** >99.0%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg

---

**HIF-1 inhibitor-1**

**Cat. No.: HY-128779**

HIF-1 inhibitor-1 is an aryl carboxamide compound and a potent hypoxia-inducible factor 1 (HIF-1) inhibitor with an IC$_{50}$ of 0.32 μM for the cancer metastasis.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 100 mg, 250 mg, 500 mg

---

**IOX2**

**Cat. No.: HY-15468**

IOX2 is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC$_{50}$ of 22 nM.

**Purity:** 98.41%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

---

**IOX4**

**Cat. No.: HY-120110**

IOX4 is a selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with an IC$_{50}$ value of 1.6 nM, induces HIFα in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

**IDF-11774**

**Cat. No.: HY-111387**

IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC$_{50}$ of 3.65μM.

**Purity:** 98.04%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

---

**JNJ-42041935**

**Cat. No.: HY-12832**

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD; inhibits PHD1, PHD2, and PHD3 with pK$_i$ values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.

**Purity:** 99.79%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg

---

**HIF-2α-IN-1**

**Cat. No.: HY-19949**

HIF-2α-IN-1 is a HIF-2α inhibitor has an IC50 of less than 500 nM in HIF-2α scintillation proximity assay.

**Purity:** 99.92%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 25 mg

---

**HIF-2α-IN-2**

**Cat. No.: HY-130264**

HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC$_{50}$ of 16 nM in scintillation proximity assay (SPA).

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

**Hydralazine hydrochloride**

**Cat. No.: HY-B0464**

Hydralazine hydrochloride is a direct-acting vasodilator that is used as an antihypertensive agent.

**Purity:** >98.0%

**Clinical Data:** Launched

**Size:** 10 mM × 1 mL, 100 mg, 500 mg

---

**IOX42041935**

**Cat. No.: HY-12832**

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD; inhibits PHD1, PHD2, and PHD3 with pK$_i$ values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.

**Purity:** 99.79%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg

---

**IDF-11774**

**Cat. No.: HY-111387**

IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC$_{50}$ of 3.65μM.

**Purity:** 98.04%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

---

**IOX2**

**Cat. No.: HY-15468**

IOX2 is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC$_{50}$ of 22 nM.

**Purity:** 98.41%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

---

**IOX4**

**Cat. No.: HY-120110**

IOX4 is a selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with an IC$_{50}$ value of 1.6 nM, induces HIFα in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

**IOX42041935**

**Cat. No.: HY-12832**

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD; inhibits PHD1, PHD2, and PHD3 with pK$_i$ values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.

**Purity:** 99.79%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg

---

**IOX2**

**Cat. No.: HY-15468**

IOX2 is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC$_{50}$ of 22 nM.

**Purity:** 98.41%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

---

**IOX4**

**Cat. No.: HY-120110**

IOX4 is a selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with an IC$_{50}$ value of 1.6 nM, induces HIFα in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

**IOX42041935**

**Cat. No.: HY-12832**

JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD; inhibits PHD1, PHD2, and PHD3 with pK$_i$ values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.

**Purity:** 99.79%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg

---

**Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com**
**Cat. No.: HY-18777**

**KC7F2**

KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC\textsubscript{50} of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent.

**Purity:** 99.61%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Cat. No.: HY-13671**

**LW6**

(LIF-1α inhibitor; LW8)

LW6 (LIF-1α inhibitor) is a novel HIF-1 inhibitor with an IC\textsubscript{50} of 4.4 μM. LW6 decreases HIF-1α protein expression without affecting HIF-1β expression.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Cat. No.: HY-111547**

**M1001**

M1001 is a weak agonist of HIF-2α, directly binds to the HIF-2α PAS-B domain, with a K\textsubscript{d} of 667 nM. M1001 enhances the stabilities of HIF-2α-ARNT complex.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Cat. No.: HY-12754**

**ML228**

(CID-46742353)

ML228 (CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) pathway, potently activate HIF in vitro as well as its downstream target VEGF.

**Purity:** >98.0%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Cat. No.: HY-12519**

**Oltipraz**

(RP 35972; NSC 347901)

Oltipraz has an inhibitory effect on HIF-1α activation in a time-dependent manner, completely abrogating HIF-1α induction at ≥10 μM concentrations, the IC\textsubscript{50} of Oltipraz for HIF-1α inhibition is 10 μM. Oltipraz is a potent Nrf2 activator.

**Purity:** 99.82%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

---

**Cat. No.: HY-N0293**

**Paeoniflorin**

(Paeoniflorin)

Paeoniflorin is a herbal constituent extracted from the root of Paeonia albiflora Pall.

**Purity:** >98.0%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 100 mg, 200 mg

---

**Cat. No.: HY-101023**

**MK-8617**

MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC\textsubscript{50} of 1 nM for PHD2.

**Purity:** >98.0%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

---

**Cat. No.: HY-12654**

**Molidustat**

(BAY 85-3934)

Molidustat (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with mean IC\textsubscript{50} values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3.

**Purity:** 98.33%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

**Cat. No.: HY-N0560**

**Oroxylin A**

(Bacalex 6-methyl ether; 6-Methoxybaicalein)

Oroxylin A is a natural active flavonoid with strong anticancer effects. IC50 value: Target: In vitro: Oroxylin A suppressed the MDM2-mediated degradation of p53 via downregulating MDM2 transcription in wt-p53 cancer cells.

**Purity:** 99.90%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg

---

**Cat. No.: HY-112441**

**Prolyl Hydroxylase inhibitor 1**

Prolyl Hydroxylase inhibitor 1 (Compound 15i) is an orally active hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor with an IC\textsubscript{50} of 62.23 nM. Antianemia agent.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 100 mg, 250 mg, 500 mg
<table>
<thead>
<tr>
<th><strong>PT-2385</strong></th>
<th>Cat. No.: HY-12867</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT-2385 is a selective HIF-2α inhibitor with a ( K_i ) of less than 50 nM.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.48%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg |

<table>
<thead>
<tr>
<th><strong>PT2399</strong></th>
<th>Cat. No.: HY-108697</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an ( IC_{50} ) of 6 nM. PT2399 displays potent antitumor activity in vivo.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.88%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

<table>
<thead>
<tr>
<th><strong>PT2977</strong></th>
<th>Cat. No.: HY-125840</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT2977 (MK-6482) is an orally active and selective HIF-2α inhibitor with an ( IC_{50} ) of 9 nM. PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. PT2977 is a potential treatment for clear cell renal cell carcinoma (ccRCC).</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.73%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg |

| **Roxadustat**  
(MK-6482) | Cat. No.: HY-13426 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g |

<table>
<thead>
<tr>
<th><strong>SYP-5</strong></th>
<th>Cat. No.: HY-100693</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.68%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

<table>
<thead>
<tr>
<th><strong>THS-044</strong></th>
<th>Cat. No.: HY-19621</th>
</tr>
</thead>
<tbody>
<tr>
<td>THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 98.48%  
**Clinical Data:** No Development Reported  
**Size:** 5 mg, 10 mg, 50 mg |

<table>
<thead>
<tr>
<th><strong>Tilorone dihydrochloride</strong></th>
<th>Cat. No.: HY-81080</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tilorone dihydrochloride is the first recognized synthetic, small molecular weight compound that is an orally active interferon inducer, used as an antiviral drug.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.94%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 100 mg, 500 mg |

<table>
<thead>
<tr>
<th><strong>TM6089</strong></th>
<th>Cat. No.: HY-118543</th>
</tr>
</thead>
<tbody>
<tr>
<td>TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** > 98%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 250 mg, 500 mg |

<table>
<thead>
<tr>
<th><strong>TP0463518</strong></th>
<th>Cat. No.: HY-112144</th>
</tr>
</thead>
<tbody>
<tr>
<td>TP0463518 is a potent hypoxia-inducible factor prolyl hydroxylases (PHDs) inhibitor with a ( K_i ) value of 5.3 nM for human PHD2. TP0463518 also inhibits human PHD1/PHD3 with ( IC_{50} ) of 18 and 63 nM as well as monkey PHD2 with an ( IC_{50} ) value of 22 nM.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 98.02%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |
### Vadadustat

**Cat. No.:** HY-101277  
**Vadadustat** is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.  

**Purity:** 99.63%  
**Clinical Data:** Launched  
**Size:** 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

### VCE-004.8

**Cat. No.:** HY-128872  
**VCE-004.8,** a semi-synthetic multitarget cannabinoquinoid, is a specific PPARγ and CB$_2$ receptor dual agonist with potent anti-inflammatory activity. VCE-004.8 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway.  

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 250 mg, 500 mg

### ZINC13466751

**Cat. No.:** HY-101028  
**ZINC13466751** is a potent inhibitor of HIF-1α/von Hippel-Lindau interaction with an IC$_{50}$ of 2.0 µM.  

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 100 mg, 250 mg, 500 mg